Search Result

Results for "

SARS-CoV-2 spike protein receptor-binding domain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (10) Angiotensin-converting Enzyme (ACE) (3) Influenza Virus (1) Virus Protease (1)
By Research Areas:	Cardiovascular Disease (1) Infection (10)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: SARS-CoV Discoidin Domain Receptor Epigenetic Reader Domain EHD Protein WDR5 YTHDF PASK/STK37 VISTA SHP1 PIKfyve BCL6 PNPLA3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99342

Imdevimab 1 Publications Verification REGN10987	SARS-CoV	Infection
Imdevimab (REGN10987) is a human monoclonal antibody that targets *SARS-CoV-2* virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .

HY-P99346

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of *SARS-CoV-2* spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of **spike protein, with a K_D** of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of *SARS-CoV-2. Beludavimab binds to recombinant spike* protein receptor-binding domain (S-RBD) with an EC₅₀ value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-P11464

SARS-CoV-2 Spike receptor binding domain, RBD (371-394)	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SARS-CoV-2 Spike receptor binding domain, RBD (371-394) is a peptide from *SARS-CoV-2* spike receptor-binding domain. SARS-CoV-2 spike protein receptor-binding domain binds to ACE2. SARS-CoV-2 Spike receptor binding domain, RBD (371-394) can be used in the research of SARS-CoV-2 infection .

HY-P991491

VIR-7229	SARS-CoV Influenza Virus	Infection
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to **SARS-CoV-2 S protein*. Anti-SARS-CoV-2* S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-P990814

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to **SARS-CoV-2 S protein*. Anti-SARS-CoV-2* S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

HY-181066

ACE2-SP PPI-IN-1	Angiotensin-converting Enzyme (ACE) SARS-CoV	Infection
ACE2-SP PPI-IN-1 is an inhibitor of the interaction between the SARS-CoV-2 spike protein and ACE2, with an IC₅₀ of 2162.77 nM. ACE2-SP PPI-IN-1 exhibits low cytotoxicity in human fibroblasts. ACE2-SP PPI-IN-1 binds to the interface region between the spike protein RBD and ACE2, reducing the flexibility of the critical receptor-binding loop and maintaining the structural compactness of the spike protein. ACE2-SP PPI-IN-1 can be used for research related to SARS-CoV-2 .

HY-N18500

(+)-Adlumidine Adlumidine	SARS-CoV Virus Protease	Cardiovascular Disease Infection
(+)-Adlumidine (Adlumidine) is an isoquinoline alkaloid. (+)-Adlumidine efficiently binds to two key targets of SARS-CoV-2, Mpro and RBD, with IC₅₀ values of 953.86 nM and 9.48 μM, respectively. (+)-Adlumidine exerts significant positive inotropic effects and certain positive chronotropic effects on cultured mouse embryonic cardiomyocytes. (+)-Adlumidine can be used for research on cardiovascular-related diseases and SARS-CoV-2 infection.

Cat. No.	Product Name	Target	Research Area

HY-P11464

SARS-CoV-2 Spike receptor binding domain, RBD (371-394)	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SARS-CoV-2 Spike receptor binding domain, RBD (371-394) is a peptide from *SARS-CoV-2* spike receptor-binding domain. SARS-CoV-2 spike protein receptor-binding domain binds to ACE2. SARS-CoV-2 Spike receptor binding domain, RBD (371-394) can be used in the research of SARS-CoV-2 infection .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99342

Imdevimab 1 Publications Verification REGN10987	SARS-CoV	Infection
Imdevimab (REGN10987) is a human monoclonal antibody that targets *SARS-CoV-2* virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .

HY-P99346

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of *SARS-CoV-2* spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of **spike protein, with a K_D** of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of *SARS-CoV-2. Beludavimab binds to recombinant spike* protein receptor-binding domain (S-RBD) with an EC₅₀ value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-P991491

VIR-7229	SARS-CoV Influenza Virus	Infection
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to **SARS-CoV-2 S protein*. Anti-SARS-CoV-2* S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-P990814

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to **SARS-CoV-2 S protein*. Anti-SARS-CoV-2* S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N18500

(+)-Adlumidine Adlumidine	Structural Classification Alkaloids Quinoline Alkaloids Plants Papaveraceae Corydalis decumbens (Thunb.) Pers. Source Classification	SARS-CoV Virus Protease
(+)-Adlumidine (Adlumidine) is an isoquinoline alkaloid. (+)-Adlumidine efficiently binds to two key targets of SARS-CoV-2, Mpro and RBD, with IC₅₀ values of 953.86 nM and 9.48 μM, respectively. (+)-Adlumidine exerts significant positive inotropic effects and certain positive chronotropic effects on cultured mouse embryonic cardiomyocytes. (+)-Adlumidine can be used for research on cardiovascular-related diseases and SARS-CoV-2 infection.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy